
PetIQ (PETQ) Stock Forecast & Price Target
PetIQ (PETQ) Analyst Ratings
Bulls say
PetIQ Inc. has demonstrated a positive financial trajectory, highlighted by a notable 20% increase in gross profit for the first quarter of 2024, reaching $74.5 million, and an improvement in gross margin by 280 basis points to 24.2%. Revenue from the Products segment rose by 6.9% to $277 million, driven by robust consumer demand in key categories such as prescription medications and flea and tick products, with manufactured product sales increasing 14% during the quarter. The company is expected to experience significant top- and bottom-line growth in the coming years, supported by the expansion of its Pet Hygiene clinics and a successful premium offering in the supplement category, which has already doubled its EBITDA run rate through enhanced distribution efforts.
Bears say
The financial outlook for PetIQ Inc. appears concerning primarily due to critical operational challenges and market risks. The company's wellness center strategy has faced significant hurdles, notably a nationwide veterinary shortage that has impacted service availability and the rollout of new centers, further complicating revenue generation. Additionally, potential threats from competitors entering the market, the risk of losing key customers, and production challenges related to value-added products could hinder the company’s performance and profitability in the near term.
This aggregate rating is based on analysts' research of PetIQ and is not a guaranteed prediction by Public.com or investment advice.
PetIQ (PETQ) Analyst Forecast & Price Prediction
Start investing in PetIQ (PETQ)
Order type
Buy in
Order amount
Est. shares
0 shares